Creso Pharma (ASX:CPH) to foray into global livestock market with anibidiol® swine

Creso Pharma Limited (ASX:CPH, FRA:1X8) has taken another step forward in its product expansion strategy by finalising the development of its new product, anibidiol® swine.

anibidiol® swine is Creso’s innovative complementary feed product based on hemp flour and oat bran. The new product supports stress reduction and wellbeing in pigs nurtured indoors and outdoors. Interestingly, anibidiol® swine provides Creso Pharma with a significant opportunity to enter the livestock market.

The Company revealed that it had developed anibidiol® swine to address tail biting in pig herds. Tail biting is a common challenge that can cause lesions and impact an animal’s value at slaughter.

Tail biting ranges in severity from light manipulation to physically harming the tail, amputation, causing infection, or even harming the surrounding areas of the tail.

Boredom, frustration, and stressful situations can also augment tail biting.

Previous reports have demonstrated a positive impact of hemp plants for reducing pig stress as well as pig tail biting.

DO READ: Creso Pharma delighted as Halucenex nearly doubles its synthetic psilocybin inventory

Development and marketing of anibidiol® swine

Creso Pharma commenced the development of anibidiol® swine in March 2020, following concerns expressed by farmers. anibidiol® swine is a Swiss-made product and in line with the European Feed Catalogue.

The Company believes that this new product will bring considerable benefits to pig herds and support stress reduction and lowering of tail biting incidences. anibidiol® swine provides appealing hemp-based animal health-focused complementary feedstock to farmers and may help address some of the concerns of pig farmers.

Creso Pharma will start marketing the new product to farmers and breeders via its already established partners and distributors in the animal health space.
News Source: KalkineMedia

Report this Page